BioCryst Reports Higher Q3 Net Income and Revenue, Raises 2026 Revenue Guidance
BioCryst Pharmaceuticals reported increases in Q3 net income and revenue and raised its revenue guidance for 2026.
Related stories
CapSek Secures Option to Raise Arctic Space Technologies Stake to About 10%
M impact | EQUITY | Nov 04, 2026, 03:08 PM UTC
Kraft Heinz to Divest Its North American Coffee Unit
Kraft Heinz will divest its North American coffee unit as part of the CEO's restructuring measures.
M impact | EQUITY | Nov 04, 2026, 03:08 PM UTC
Kraft Heinz plans to sell its North American coffee division
The planned sale is part of turnaround measures introduced by the company's chief executive.
M impact | EQUITY | Nov 04, 2026, 03:07 PM UTC
Teka Construction Posts Quarterly Profit of 3.52 Million Baht
M impact | EQUITY | Nov 04, 2026, 03:07 PM UTC
AMTD: trading halted on NYSE — additional information requested (last $13.90)
NYSE halted trading in AMTD (additional information requested). Last price $13.90.
L impact | EQUITY | Nov 04, 2026, 03:07 PM UTC
Melco Resorts Shares Rise After Q3 Adjusted Earnings Beat Estimates
M impact | EQUITY | Nov 04, 2026, 03:07 PM UTC